More Ups Than Downs In Latest Drug Price Adjustment
This article was originally published in PharmAsia News
China's National Development and Reform Commission (NDRC) recently adjusted the price of 47 formulations for 26 types of generic drugs, including Mycetozoan and Rifampicin. While the previous 24 adjustments focused on lowering prices, the latest round raised the price of most drugs, up to six-fold. Analysts note that this adjustment will benefit industry development and protect the interests of local manufacturers producing cheap medicines with good quality. It could also indicate a new trend of drug price adjustment. However, others caution against relying on a single instance as a reflection of future policy. (Click here for more)
You may also be interested in...
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?